Biotech M&A on Track for Strongest Year Since Pre-Covid
Global biopharma mergers and acquisitions are experiencing a surge in 2026, reaching $106 billion across 201 deals so far. This momentum is driven by patent cliffs, buoyant public markets, and Big Pharma's need to strengthen pipelines. Despite deteriorating interest rates due to inflationary pressures from the Iran war, dealmaking remains robust.
Tickers: $HSBC
Topics: biotech mergers and acquisitions patent cliffs pharmaceuticals public markets